Alliance Pharma plc

Alliance Pharma plc is a pharmaceutical firm with an expansive global reach, conducting business across Europe, the Middle East, Africa, the Asia Pacific region, China, and the Americas. The company's core activities involve sourcing, promoting, and distributing a diverse array of consumer healthcare items and prescribed medications. It currently manages the marketing rights for approximately 80 different products within these categories. Additionally, its offerings extend to medical devices, dietary supplements, and cosmetic goods. Notable brands within its portfolio include Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen. Founded in 1996, Alliance Pharma plc maintains its corporate base in Chippenham, United Kingdom.

Alliance Pharma plc trades as APH.L on LSE. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in GBP.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £178.84M of revenue and -£10.73M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Alliance Pharma plc can be compared against peers such as Arix Bioscience plc, Benchmark Holdings plc, Celadon Pharmaceuticals Plc, Hellenic Dynamics Plc, Instem plc, Medica Group Plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £349.75M, beta of 0.58, and return on equity of -5.2%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

APH.L currently shows total debt of £95.70M and beta of 0.58. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.alliancepharmaceuticals.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.